Dogma Therapeutics, a Viva Biotech portfolio company, has signed a contract for the acquisition of the oral PCSK9 programme of United Kingdom-based AstraZeneca, it was reported on Thursday.
The deal will allow Dogma to receive upfront and downstream funding related to global regulatory and commercial milestones.
Dr Zhixiong Ye, chief scientific officer at Viva Biotech, said, 'Viva Biotech has begun to incubate and invest in Dogma Therapeutics since 2017. It was an exceptionally rewarding experience for our team to have a close partnership with Dogma during the exciting discovery phase. An orally-bioavailable small molecule PCSK9 inhibitor will greatly impact the unmet medical needs of cardiovascular patients.'
AnnJi Pharmaceutical secures FDA Fast Track Designation for AJ201 in rare neuromuscular disease
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director